OA11728A - Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same. - Google Patents

Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same. Download PDF

Info

Publication number
OA11728A
OA11728A OA1200100150A OA1200100150A OA11728A OA 11728 A OA11728 A OA 11728A OA 1200100150 A OA1200100150 A OA 1200100150A OA 1200100150 A OA1200100150 A OA 1200100150A OA 11728 A OA11728 A OA 11728A
Authority
OA
OAPI
Prior art keywords
polymer
set forth
molécule
pharmaceutically active
compound
Prior art date
Application number
OA1200100150A
Other languages
English (en)
Inventor
Stephen J Comiskey
Stephen J Hanley
Rachel S Kohn
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of OA11728A publication Critical patent/OA11728A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
OA1200100150A 1998-12-16 1999-11-22 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same. OA11728A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21298698A 1998-12-16 1998-12-16

Publications (1)

Publication Number Publication Date
OA11728A true OA11728A (en) 2005-02-01

Family

ID=22793267

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100150A OA11728A (en) 1998-12-16 1999-11-22 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same.

Country Status (35)

Country Link
EP (1) EP1140026B1 (sr)
JP (1) JP4759141B2 (sr)
KR (1) KR100707710B1 (sr)
CN (1) CN1195497C (sr)
AP (1) AP1769A (sr)
AR (1) AR021652A1 (sr)
AT (1) ATE303795T1 (sr)
AU (1) AU770673B2 (sr)
BG (1) BG65500B1 (sr)
BR (1) BR9916276A (sr)
CA (1) CA2355077C (sr)
CR (1) CR6424A (sr)
CZ (1) CZ301947B6 (sr)
DE (1) DE69927177T2 (sr)
DK (1) DK1140026T3 (sr)
EA (1) EA004502B1 (sr)
EE (1) EE200100314A (sr)
ES (1) ES2245128T3 (sr)
HK (1) HK1041645B (sr)
HR (1) HRP20010446A2 (sr)
HU (1) HU226586B1 (sr)
ID (1) ID28909A (sr)
IL (2) IL143761A0 (sr)
ME (2) MEP19408A (sr)
NO (1) NO20012981L (sr)
NZ (1) NZ511962A (sr)
OA (1) OA11728A (sr)
PL (1) PL196822B1 (sr)
RS (1) RS50123B (sr)
SK (1) SK285812B6 (sr)
TR (1) TR200101759T2 (sr)
TW (1) TWI221418B (sr)
UA (1) UA73101C2 (sr)
WO (1) WO2000035423A1 (sr)
ZA (1) ZA200104899B (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061932A1 (de) * 2000-12-13 2002-10-24 Pharmatech Gmbh Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
WO2002075273A2 (en) * 2001-03-20 2002-09-26 Euroscreen S.A. Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
PT1392248E (pt) 2001-05-23 2007-10-11 Hexal Ag Processo para a preparação de implantes por meio da preparação de um homogeneizado sem solvente
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US8691277B2 (en) * 2004-09-21 2014-04-08 Shandong Luye Pharmaceutical Co., Ltd. Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CN102159193B (zh) * 2008-09-18 2015-09-16 普渡制药公司 包含聚(ε-己内酯)的药物剂型
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010151746A2 (en) * 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
CN114901064B (zh) * 2019-12-31 2024-03-08 万卡坦卡有限公司 延长释放塑料配方

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
CH679207A5 (sr) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
ES2185615T3 (es) * 1990-05-16 2003-05-01 Southern Res Inst Uso y liberacion controlada de las microcapsulas para estimular el crecimiento de la fibra nerviosa.
WO1991018602A1 (en) * 1990-06-01 1991-12-12 Merrell Dow Pharmaceuticals Inc. (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5505963A (en) * 1993-04-07 1996-04-09 Schwartz Pharma Ag Slow release pharmaceutical preparation
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
AU4467396A (en) * 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm

Also Published As

Publication number Publication date
WO2000035423A1 (en) 2000-06-22
CZ301947B6 (cs) 2010-08-11
NO20012981D0 (no) 2001-06-15
BR9916276A (pt) 2001-09-04
CA2355077C (en) 2009-05-26
KR20010082359A (ko) 2001-08-29
EA004502B1 (ru) 2004-04-29
TWI221418B (en) 2004-10-01
IL143761A (en) 2006-08-01
AU1742500A (en) 2000-07-03
WO2000035423A9 (en) 2002-08-22
HK1041645B (zh) 2005-07-29
CZ20012157A3 (cs) 2001-09-12
JP2002532408A (ja) 2002-10-02
PL348233A1 (en) 2002-05-20
AU770673B2 (en) 2004-02-26
DK1140026T3 (da) 2006-01-02
HK1041645A1 (en) 2002-07-19
HUP0105048A2 (hu) 2002-05-29
NZ511962A (en) 2003-06-30
EE200100314A (et) 2002-08-15
EP1140026B1 (en) 2005-09-07
YU41401A (sh) 2003-12-31
BG65500B1 (bg) 2008-10-31
SK8282001A3 (en) 2001-11-06
MEP19408A (en) 2010-06-10
DE69927177T2 (de) 2006-06-08
CN1330536A (zh) 2002-01-09
EA200100551A1 (ru) 2001-10-22
SK285812B6 (sk) 2007-08-02
ES2245128T3 (es) 2005-12-16
PL196822B1 (pl) 2008-02-29
CA2355077A1 (en) 2000-06-22
CR6424A (es) 2004-02-26
HU226586B1 (en) 2009-04-28
NO20012981L (no) 2001-07-27
ATE303795T1 (de) 2005-09-15
ZA200104899B (en) 2002-09-16
BG105591A (en) 2002-01-31
DE69927177D1 (de) 2005-10-13
HRP20010446A2 (en) 2002-06-30
AR021652A1 (es) 2002-07-31
TR200101759T2 (tr) 2001-12-21
KR100707710B1 (ko) 2007-04-18
ID28909A (id) 2001-07-12
AP1769A (en) 2007-08-22
JP4759141B2 (ja) 2011-08-31
HUP0105048A3 (en) 2002-09-30
RS50123B (sr) 2009-03-25
IL143761A0 (en) 2002-04-21
ME00066B (me) 2010-06-10
EP1140026A1 (en) 2001-10-10
AP2001002198A0 (en) 2001-09-30
CN1195497C (zh) 2005-04-06
UA73101C2 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
CA2355077C (en) Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
US6455526B1 (en) Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
EP2968320B1 (en) Organic compounds
FI122717B (fi) Menetelmä valmistaa tramadolihydrokloridia hallitusti vapauttava valmiste
RU2696578C1 (ru) Технология приготовления таблеток для cgrp-активных соединений
JP2012193186A (ja) 放出制御製剤処方物、単位用量形態、乾燥顆粒、マルチ粒子、調製方法、共重合体の使用、および製剤処方物における耐改ざん性を付与する方法
HUE033554T2 (en) Dosage form with difficult / inhibited abuse
CN117715625A (zh) 用于治疗晶体和非晶体相关急性炎症性关节炎的包含秋水仙碱的关节内注射用剂型
EP3454837B1 (en) Use of amino sugar as plasticizer
CA2273272C (en) Immediate release drug delivery forms
MXPA01005920A (es) Antagonista del receptor de serotonina encapsulada de polimero biodegradable y metodo para preparar el mismo
WO1999047175A1 (en) Pharmaceutical compositions containing melatonin inclusion complexes
CN1297448A (zh) 帕罗西汀抗坏血酸盐
Kallakunta A Novel Dimension of Twin-Screw Technology for Controlled Release and Solubility Enhancement: Study on Effect of Formulation and Process Parameters
JP2012515764A (ja) 非ステロイド系抗炎症薬およびコルチコシド誘導体を含有する有効成分の新規な組み合わせ
HK1092715A1 (en) Melt-formulated, multi-particulate oral dosage form